biostudies-literatureUnknown8(17)Du CGastric cancer is currently the second leading cause of cancer-related death worldwide, especially in Japan, Korea and China, and the 5-year survival rate of gastric cancer is less than 30%. Thus, it is important to shed more lights on novel agents to prevent gastric cancer or to improve survival rate of the patients. Vitamin D not only maintains calcium and bone homeostasis, but also mostly inhibits tumor genesis, invasion, and metastasis through activation of vitamin D receptor. Although epidemiological results are not consistent, accumulating evidence from gastric cancer cells, animal models, and clinical trials suggest that vitamin D deficiency may increase the risk and mortality of gastric cancer, but vitamin D supplement might be a safe and economical way to prevent or treat gastric Oncotarget29474-29486https://www.ebi.ac.uk/biostudies/studies/S-EPMC5438745biostudies-literaturePathogenic roles of alterations in vitamin D and vitamin D receptor in gastric tumorigenesis.PMC5438745Du CDong HYang SZhao XfalsePathogenic roles of alterations in vitamin D and vitamin D receptor in gastric tumorigenesis.Gastric cancer is currently the second leading cause of cancer-related death worldwide, especially in Japan, Korea and China, and the 5-year survival rate of gastric cancer is less than 30%. Thus, it is important to shed more lights on novel agents to prevent gastric cancer or to improve survival rate of the patients. Vitamin D not only maintains calcium and bone homeostasis, but also mostly inhibits tumor genesis, invasion, and metastasis through activation of vitamin D receptor. Although epidemiological results are not consistent, accumulating evidence from gastric cancer cells, animal models, and clinical trials suggest that vitamin D deficiency may increase the risk and mortality of gastric cancer, but vitamin D supplement might be a safe and economical way to prevent or treat gastric 2017-01-01T00:00:00Z2017 Apr2025-04-21T18:47:34.639Z2020-11-19T16:52:03ZS-EPMC54387452820697810.18632/oncotarget.15298